National Institute for Health and Clinical Excellence (NICE)
Evidence for HTA: Innovative methods for challenging times
Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of HTAi 2021 in the UK.
Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of HTAi 2021 in the UK, her part in planning the scientific programme and how the meeting will encourage debate and discussion around the latest advances in defining, generating and using evidence in healthcare decision making
Next year NICE will co-host the 18th Health Technology Assessment International (HTAi) Annual Meeting from 19-23 June in Manchester, UK. Health Technology Assessment (HTA) is defined as “a multidisciplinary process that uses explicit methods to determine the value of a health technology at different points in its lifecycle. The purpose is to inform decision-making in order to promote an equitable, efficient, and high-quality health system” (the International Network of Agencies for Health Technology Assessment (INAHTA)).
HTA agencies like NICE around the world assess the value of new health technologies and advise on whether or not, and how a technology might be used effectively within a healthcare system. The hybrid meeting, with the option to participate virtually, will bring the global HTA community together to network, collaborate and forge new partnerships.
At NICE we have been working closely with HTAi to bring together a programme which is framed around the main theme of ‘Innovation through HTA’. This theme reflects the changing times we live in, the rapid pace at which technology advances and of course the swift global response which has been forced by COVID-19.
During International Scientific Programme Committee meetings, there has been an extensive range of suggested discussion topics which has made my role extremely challenging, but also interesting! I worked with the HTAi secretariat, International Scientific Programme Committee and its working groups to pull together the vast array of discussion points, issues for exploration and questions into three cohesive plenary themes:
- evidence for HTA: innovative methods for challenging times
- patients at the heart of innovation
- innovating HTA to support novel interventions
As NICE is an official partner of the inaugural World Evidence-based Healthcare Day coming up on 20 October, it seems fitting that the HTAi 2021 Annual Meeting will provide a unique opportunity for both those generating and those using the evidence to come together and discuss the key issues relating to the evolving evidence ecosystem.
The first plenary theme, ‘Evidence for HTA: Innovative methods for challenging times’, will examine how the rapid pace and scale of technological development, have led to traditional approaches to evidence production, review and synthesis being seen as potentially hindering the innovation process and delaying access to innovative health technologies. This plenary aims to drive forward ongoing debate on how the evidence eco-system is, and should continue, changing and adapting to meet the HTA and healthcare systems’ challenges of today, and tomorrow.
If you are keen to join us at HTAi 2021, you can find out more about the meeting themes and how to submit an abstract by visiting the meeting website. Abstract submissions for oral, poster and vignette presentations are currently being accepted and the deadline is Thursday 26 November.
We look forward to your participation!
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
Professor Gillian Leng to retire from NICE09/09/2021 14:15:00
Professor Leng has spent more than 20 years working at NICE.
NICE draft guidance recommends apalutamide for treating prostate cancer08/09/2021 12:20:00
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults
Sharing evidence with NICE is part of a broader approach to help Cochrane to identify priority reviews02/09/2021 11:15:00
Toby Lasserson, deputy editor in chief at Cochrane, writes about a new collaborative agreement with NICE, how it will work and what it means for the health service.
NICE approves ground-breaking cholesterol-lowering drug inclisiran01/09/2021 13:05:00
NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke
NICE and Cochrane sign collaborative agreement to deliver ‘living’ guideline recommendations01/09/2021 12:05:00
NICE and Cochrane have today (01st September 2021) signed a collaborative agreement which will help to deliver ‘living’ recommendations across the NICE guideline portfolio.
NICE announces next steps for ME/CFS guideline31/08/2021 09:15:00
NICE recognises the importance to patients of the updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) and is keen to move forwards as quickly as possible.